Open Application

Altoida is at the forefront of revolutionizing brain health diagnostics, addressing a critical challenge faced by millions of patients and their families: the late detection of neurological diseases like Alzheimer's. Traditional cognitive assessments are often lengthy, subjective, and lack the sensitivity to detect the subtle changes that signal the onset of conditions such as Mild Cognitive Impairment (MCI). This delay in diagnosis means that patients often miss a crucial window for intervention when treatments could be most effective. To solve this, Altoida has developed a pioneering digital NeuroMarker Platform, designed to empower healthcare providers with the tools for early and accurate detection. Our customers, who range from primary care physicians to specialists in neurology, need a way to quickly and objectively assess a patient's cognitive health during a standard clinic visit. The platform provides a solution that is both patient-centric and efficient for clinicians.

Our innovative approach utilizes a simple, 10-minute self-administered assessment on a smart tablet. By combining advanced neuroscience with the immersive power of augmented reality (AR), we simulate activities of daily living to capture hundreds of digital biomarkers. This data, spanning motor skills, speech, and cognitive functions, is then analyzed by our sophisticated machine learning algorithms. This process provides healthcare professionals with real-time, objective results, enabling them to identify at-risk individuals much earlier than traditional methods allow. For patients, this means a non-invasive and engaging experience that puts them at the center of their own cognitive health journey. By providing this deeper, evidence-based insight, we help clinicians make more informed and timely decisions, personalize treatment plans, and track disease progression effectively. Ultimately, Altoida is dedicated to transforming the standard of care in neurology, making early intervention a reality and improving the lives of those affected by neurodegenerative diseases.